^
    Back
    Association details:
    Biomarker:CD74-ROS1 fusion
    Cancer:Lung Adenocarcinoma
    Drug:cisplatin (DNA synthesis inhibitor) +
    pemetrexed (Thymidylate synthase inhibitor, THF dehydrogenase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    The Oncologist
    Title:

    Acquired MET D1228N Mutations Mediate Crizotinib Resistance in Lung Adenocarcinoma with ROS1 Fusion: A Case Report

    Published date:
    09/20/2020
    Excerpt:
    An NGS‐based 123‐gene panel assay for common driver genes showed CD74‐ROS1 fusion and wild‐type EGFR/ALK...The patient underwent one cycle of cisplatin and pemetrexed combination chemotherapy, and CT scan of the chest showed partial response with lung lesion shrinkage.
    DOI:
    10.1002/onco.13545